Drug Approval | June 27, 2023
USFDA approves Pfizer’s Litfulo for adults and adolescents with severe alopecia areata
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
Mix-n-Stain CF Dye IgM Antibody Labeling Kits address longstanding challenges for labeling IgM antibodies by offering efficient and convenient conjugation with bright CF Dyes
The booster vaccine can be administered safely to individuals who have received two doses of either Covaxin or Covishield
Dignitaries and delegates commend India’s leadership in Global South during G20 India Presidency
Despite nearly 20 years of availability, biosimilars show worldwide adoption rate of only 14% in initiative-tracked countries, while reference medicines still represent 86% of biologic
Granules now has a total of 58 ANDA approvals from US FDA
Survey of Unmet Needs in chronic myeloid leukemia (CML SUN) data signal need for amplified patient voice during treatment discussions that balance quality of life (QoL), efficacy, and tolerability goals across all lines of therapy
Acquisition accelerates Cosette’s women’s health portfolio; with a differentiated, commercial stage, patent protected product
Tremelimumab in combination with Durvalumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC)
Subscribe To Our Newsletter & Stay Updated
